That this House welcomes the Queen's Jubilee Medal which will honour those serving in the UK's armed forces and emergency services who risk their lives in support of the public; but asks the Government to consider extendingthe award of the Queen's JubileeMedal to volunteer organisations such as St John Cymru Wales in order to recognise the over 18,000 people they train in first aid who offer life-saving skills as community first responders in assisting the emergency services.

That this House welcomes the Queen's Jubilee Medal which will honour those serving in the UK's armed forces and emergency services who risk their lives in support of the public; but asks the Government to consider extendingthe award of the Queen's JubileeMedal to volunteer organisations such as St John Cymru...

That this House recognises that the Government has no mandate to change the current system for elections to the Welsh Assembly; and believes that any proposals for change to that system should be put for decision by the people of Wales.

That this House recognises that the Government has no mandate to change the current system for elections to the Welsh Assembly; and believes that any proposals for change to that system should be put for decision by the people of Wales.

That this House commends the work of Gwent Theatre which has provided an excellent theatre in education experience for young people and schools in South East Wales for over 30 years and has played a hugely supportive role for Gwent Young People's theatre and led to many young people pursuing a career in the performing arts; deplores the withdrawal of their funding by Arts Council Wales and that body's lack of transparency in making this decision; is alarmed that this will lead to the company closing in February leaving South East Wales, including some of the most deprived communities in Wales, with no theatre in education provision; and calls on Arts Council Wales to reverse this decision immediately in light of the vigorous community campaign and scrutiny by the Communities and Culture and Petitions Committees in the Welsh Assembly.

That this House commends the work of Gwent Theatre which has provided an excellent theatre in education experience for young people and schools in South East Wales for over 30 years and has played a hugely supportive role for Gwent Young People's theatre and led to many young people pursuing...

That this House expresses concern at the ruling by the National Institute for Health and Clinical Excellence (NICE) in its final appraisal determination which will in effect deny a new treatment, Velcade, to people suffering from multiple myeloma on the NHS; recognises that this will create inequity in the Health Service in England and Wales where patients with private insurance will continue to have access to this life-extending treatment; notes that while NICE recognises its clinical effectiveness, the decision to withhold it from NHS patients has been made on the grounds of cost; further notes that other European countries have been able to assess the drug as both clinically and cost effective; acknowledges that NICE currently caps the cost of treatments at ??30,000 per quality added life year, which is inappropriate in the assessment of rare diseases and should be set substantially higher; and in the light of this calls on the Secretary of State for Health to ask NICE to review urgently again its processes for the assessment of treatments for less common cancers such as multiple myeloma.

That this House expresses concern at the ruling by the National Institute for Health and Clinical Excellence (NICE) in its final appraisal determination which will in effect deny a new treatment, Velcade, to people suffering from multiple myeloma on the NHS; recognises that this will create inequity in the Health...

That this House expresses regret that First Great Western has reduced the number of services stopping at Severn Tunnel Junction during peak times; notes that these services are a vital link for hundreds of commuters travelling to Cardiff and Bristol for work; further notes with concern that the average person travelling by rail generates around half the carbon dioxide emissions of the average person travelling by car and that this reduction in service will force people into their cars for these journeys and undermine efforts to reduce carbon emissions; further notes that First Great Western has pledged to reintroduce the services from May onwards but that this will severely disrupt the lives and working patterns of many people; believes that the flaws and inaccuracy in the consultation process prevented this matter being rectified sooner; and calls on the Government to urge First Great Western and Network Rail to provide a timetable that includes these vital services for commuters by reintroducing the peak time stops at Severn Tunnel Junction from 11th December.

That this House expresses regret that First Great Western has reduced the number of services stopping at Severn Tunnel Junction during peak times; notes that these services are a vital link for hundreds of commuters travelling to Cardiff and Bristol for work; further notes with concern that the average person...

That this House expresses concern at the ruling by the National Institute for Health and Clinical Excellence (NICE) in its final appraisal determination which will in effect deny a new treatment, Velcade, to people suffering from multiple myeloma on the NHS; recognises that this will create inequity in the health service in England and Wales where patients with private insurance will continue to have access to this life-extending treatment; notes that while NICE recognises its clinical effectiveness, the decision to withhold it from NHS patients has been made on the grounds of cost; further notes that other European countries have been able to assess the drug as both clinically and cost-effective; acknowledges that NICE currently caps the cost of treatments at ??30,000 per quality added life year, which is inappropriate in the assessment of rare diseases and should be set substantially higher; and in the light of this calls on the Secretary of State for Health to ask NICE to review urgently again its processes for the assessment of treatments for less common cancers such as multiple myeloma.

That this House expresses concern at the ruling by the National Institute for Health and Clinical Excellence (NICE) in its final appraisal determination which will in effect deny a new treatment, Velcade, to people suffering from multiple myeloma on the NHS; recognises that this will create inequity in the health...

That this House notes with concern that the National Institute for Health and Clinical Excellence's (NICE) Single Technology Appraisal Consultation Document on Velcade does not recommend this treatment for use in the NHS except as part of ongoing or new clinical trials; further notes that this is the only new treatment licensed for use in myeloma patients in the past 10 years and represents a major step forward in the treatment of this cancer, which has one of the highest death rates of all cancers; recognises that this treatment has been positively appraised by the Scottish Medicines Consortium and the All Wales Medicines Strategy Group, currently making it available to patients in Scotland and Wales, and that within its licence it has been endorsed for use by the UK Myeloma Forum and the British Committee for Standards in Haematology; further notes that the clinical and cost-effectiveness analysis of this treatment demonstrates that the cost per life year gained was between ??28,000 and ??31,000 for treatment at first relapse, which is within the NICE requirements for cost effectiveness; and therefore requests that the Secretary of State for Health asks NICE to reconsider the evidence before issuing its final appraisal determination.

That this House notes with concern that the National Institute for Health and Clinical Excellence's (NICE) Single Technology Appraisal Consultation Document on Velcade does not recommend this treatment for use in the NHS except as part of ongoing or new clinical trials; further notes that this is the only new...

That this House notes the exorbitant cost of incoming calls to patients in hospitals, which exploits family and friends keeping in touch with loved ones; supports the concerns of consumers about the prices charged by service providers Patientline and Premier, who can charge up to 49p per minute peak and 39p per minute off-peak; welcomes the investigation by Ofcom; and supports its recommendation that the Department of Health urgently review all aspects of the installation and operation of bedside telephone and entertainment systems in hospitals.

That this House notes the exorbitant cost of incoming calls to patients in hospitals, which exploits family and friends keeping in touch with loved ones; supports the concerns of consumers about the prices charged by service providers Patientline and Premier, who can charge up to 49p per minute peak and...

That this House congratulates the International Myeloma Foundation (UK) (IMF (UK)) on its seventh UK Myeloma Awareness Week, being held from 21st to 28th June; recognises the work IMF (UK) undertakes to provide information and support to those living with this debilitating form of bone marrow cancer and to improve standards of treatment and care through education and research; notes that despite significant Government investment in cancer services there are still some variations in the availability of the latest cancer treatments to myeloma patients across the UK; calls on the Government to ensure that the National Institute for Health and Clinical Excellence reviews the latest myeloma treatments as soon as possible and that patients with myeloma have access to the best possible treatments as soon as they are licensed, when clinically needed, with the support of their consultant haematologist; and calls for local funding to continue to be made available for all patients with myeloma.

That this House congratulates the International Myeloma Foundation (UK) (IMF (UK)) on its seventh UK Myeloma Awareness Week, being held from 21st to 28th June; recognises the work IMF (UK) undertakes to provide information and support to those living with this debilitating form of bone marrow cancer and to improve...